Imaging tumor sensitivity to a bioreductive prodrug: Two for the price of one!

Clinical Cancer Research

Volumn 18, Issue 6, 2012, Pages 1487-1489

  Brown, J Martin ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE F 18; ANTINEOPLASTIC AGENT; CEN 209; FLUORINE 18; NITROREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE; TIRAPAZAMINE; TRACER; UNCLASSIFIED DRUG;

ARTICLE; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG METABOLISM; DRUG SELECTIVITY; DRUG SENSITIVITY; ENZYME ACTIVITY; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IONIZING RADIATION; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR;

ANIMALS; CALCIUM-BINDING PROTEINS; CELL CYCLE PROTEINS; ETANIDAZOLE; FEMALE; HUMANS; HYDROCARBONS, FLUORINATED;

EID: 84863272778     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3267     Document Type: Article

References (8)

1. Wang J, Foehrenbacher A, Su J, Patel R, Hay MP, Hicks KO, et al. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia. Clin Cancer Res 2012;18:1684-95.
2. Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck - a systematic review and meta-analysis. Radiother Oncol 2011;100:22-32.
3. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-47. (Pubitemid 38745529)
4. Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010;28:2989-95.
5. Peters LJ, O'Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG02.02. J Clin Oncol 2010;28:2996-3001.
6. Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, et al. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin Cancer Res 2010;16:4946-57.
7. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006;24:2098-104.
8. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med 2008;49:1944-51.